Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.62 |
| ▸ | CA2 | P00918 | 8/20 | 0.62 |
| ▸ | CA9 | Q16790 | 6/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 5/20 | 0.48 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL866410 | 0.88 | CA1 (0.71) | CA1CA2CA9HTTCA12 | |
| SCHEMBL28326326 | 0.81 | HTT (0.66) | CA1CA2CA9HTTCA12 | |
| SCHEMBL28363779 | 0.81 | CA1 (0.62) | CA1CA2CA9HTTCA12 | |
| SCHEMBL4826239 | 0.81 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| SCHEMBL28326328 | 0.80 | HTT (0.64) | CA1CA2CA9HTTCA12 | |
| SCHEMBL8690274 | 0.77 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| Potassium Ion SCHEMBL1902294 | 0.77 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| SCHEMBL866411 | 0.77 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| SCHEMBL31634023 | 0.77 | CA1 (0.67) | CA1CA2CA9HTTCA12 | |
| SCHEMBL11704991 | 0.77 | CA1 (0.67) | CA1CA2CA9HTTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211146-B1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | UNIV BAR ILAN (IL) | 2026-05-20 | — | — | EP | disclosed |
| US-12616760-B2 | Synthetic cyclic peptide mimetics | BAR ILAN UNIVERSITY (IL) | 2026-05-05 | — | — | US | disclosed |
| EP-4702010-A1 | PHOTOACTIVE COMPOUNDS | Merck Patent GmbH (DE) | 2026-03-04 | — | — | EP | disclosed |
| CN-114751950-B | Cyclic dinucleotide compounds and methods of use | 免疫传感器公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2024223739-A1 | PHOTOACTIVE COMPOUNDS | MERCK PATENT GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| US-20240316225-A1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | BAR ILAN UNIVERSITY (IL) | 2024-09-26 | — | — | US | disclosed |
| US-11879021-B2 | Cyclic peptides and uses thereof | Université de Montréal | 2024-01-23 | — | — | US | disclosed |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4211146-A1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | Bar Ilan University (IL) | 2023-07-19 | — | — | EP | disclosed |
| US-11597746-B2 | Cyclic dinucleotides as sting agonists | JANSSEN BIOTECH, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3475293-A1 | NOVEL CYCLIC PEPTIDES AND USES THEREOF | Valorisation-Recherche, Limited Partnership (CA) | 2019-05-01 | — | — | EP | disclosed |
| EP-3429596-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | Immune Sensor, LLC (US) | 2019-01-23 | — | — | EP | disclosed |
| CN-108727249-A | The synthetic method of 3- difluoromethyls piperidine hydrochlorate and its derivative | 台州学院 | 2018-11-02 | — | — | CN | disclosed |
| WO-2018000079-A1 | NOVEL CYCLIC PEPTIDES AND USES THEREOF | VALORISATION-RECHERCHE, LIMITED PARTNERSHIP (CA) | 2018-01-04 | — | — | WO | disclosed |
| WO-2017161349-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE | IMMUNE SENSOR, LLC (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2016029324-A1 | AZASULFURYLPEPTIDE-BASED CD36 MODULATORS AND USES THEREOF | RSEM, LIMITED PARTNERSHIP (CA) | 2016-03-03 | — | — | WO | disclosed |
| EP-0772618-B1 | REGIOSELECTIVE SULFATION | GENZYME LTD (GB) | 2002-04-03 | — | — | EP | disclosed |
| US-5874548-A | SELECTIVELY SULFATED MONO-, DI- AND OLIGOSACCHARIDES, AND THEIR CONJUGATES WHICH ARE INVOLVED IN DIVERSE BIOLOGICAL PROCESSES; PRODUCED EFFICIENTLY WITH LESS PROTECTING/DEPROTECTING STEPS | GENZYME CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
| US-4150223-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1979-04-17 | — | — | US | disclosed |
| US-4032521-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1977-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11879021-B2 | Cyclic peptides and uses thereof | GHRHR, GHSR, GIPR | CA1 4293/4885CA2 3674/4885CA9 3349/4885 |
| US-12616760-B2 | Synthetic cyclic peptide mimetics | TPX2, IAPP, HAX1 | CA1 208/4885CA2 2097/4885CA9 792/4885 |
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | CA1 4807/4885CA2 4072/4885CA9 4739/4885 |
| US-20240316225-A1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | IAPP, QPCTL, DNPEP | CA1 304/4885CA2 3035/4885CA9 722/4885 |
| US-11597746-B2 | Cyclic dinucleotides as sting agonists | STING1, CGAS, IFNAR1 | CA1 4809/4885CA2 4118/4885CA9 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.